HOME >> MEDICINE >> NEWS
Mayo Clinic researchers report on effectiveness of treatments for hot flashes

; Sunday, May 15, 2005, 8 a.m. EDT

NCCTG Study Compares Venlafaxine and Progestational Agents in Reducing Hot Flashes

Mayo Clinic researchers will outline current data comparing the effectiveness of two medicines -- venlafaxine and a progestational agent -- in combating hot flashes.

Previous studies have shown that both venlafaxine and progestational agents substantially decrease hot flashes. This NCCTG trial demonstrated that a single dose of the progestational agent, medroxyprogesterone acetate (MPA), alleviated hot flashes more than did the daily use of the oral antidepressant venlafaxine (Effexor). Three to four weeks after treatment began, researchers observed that MPA was more effective than venlafaxine. This difference became even more striking after six weeks of treatment, says Mayo medical oncologist Charles Loprinzi, M.D., the NCCTG study's lead investigator.

"This improved hot flash benefit appeared to last for at least six months following a single MPA dose, with almost three times as many patients still reporting a 90 percent hot flash reduction following MPA versus patients receiving daily oral venlafaxine," says Dr. Loprinzi.

The findings reviewed in this presentation include data from 185 patients. Six weeks after treatment was started (compared to the baseline week), patients who received the single shot of MPA, versus those on venlafaxine, had greater reductions in median hot flash frequencies (85 percent vs. 52 percent reduction) and reductions in median hot flash scores (88 percent vs. 57 percent reduction).

Mayo researchers also noted that 24 percent of patients who received MPA reported no hot flashes after six weeks compared to 1 percent of venlafaxine patients. Patients on MPA also reported less trouble sleeping, less sleepiness, less constipation, less abnormal sweating and less hot flash distress than patients on venlafaxine.

The patients on venlafaxine had trends for less trou
'"/>


15-May-2005


Page: 1 2 3 4

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression

Post Your Comments:
(Date:5/24/2015)... 24, 2015 ProPin is a set ... Pro X. Utilize ProPin to pin point locations on a ... , ProPin allows users to choose from 30 simplistic ... With on-screen controls, video editors can easily manipulate ProPin presets ... and mark with absolute ease. , Using ProPin is easy, simply ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers ... Florida City exactly five years to the day after the ... A large fire tore through the Branches United Methodist Church ... the middle of the night as neighbors, staff and Branches' ... even though it is suspected that the fire began accidentally. ...
(Date:5/23/2015)... Parker, CO (PRWEB) May 23, 2015 On ... participated in MuckFest. The event was a 5k mud obstacle ... affects more than 2 million people worldwide, and the reason ... our community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. ... National Multiple Sclerosis Society.” , The event was not only ...
(Date:5/23/2015)... 23, 2015 Injury lawyer Steven H. Heisler ... passed by the Maryland legislature but which has not been ... Assembly passed HB 449 with overwhelming bipartisan support ... signed it into law. This bill ensures that fracking is ... that demonstrates the danger of fracking to our water supplies ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board of ... Chief Financial Officer (CFO), will be leaving the organization ... company CFO since 2011. , The Board of Trustees ... system as CFO. Wesley will oversee the health system’s ... of Trustees conducts a formal search for a replacement. ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... According to a new market ... Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020", published by ... reach $736.85 Million by 2020 from $452.36 Million in ... Browse 71 market data Tables and 90 Figures ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
Cached News: